Steven Seedhouse
Stock Analyst at Cantor Fitzgerald
(3.17)
# 1,193
Out of 5,090 analysts
161
Total ratings
47.1%
Success rate
0.72%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATXS Astria Therapeutics | Downgrades: Neutral | n/a | $13.10 | - | 3 | Nov 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $7.86 | +231.00% | 2 | Oct 15, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $56 → $63 | $44.90 | +40.33% | 4 | Sep 9, 2025 | |
| KRRO Korro Bio | Maintains: Strong Buy | $153 → $147 | $6.97 | +2,009.04% | 3 | Aug 13, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $71.71 | +14.35% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $7.56 | +32.28% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $27.82 | +0.67% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $1.11 | +804.98% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $38.86 | +167.63% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $3.56 | +517.98% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $2.15 | +552.68% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $122.42 | -24.03% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $42.61 | +59.59% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $22.05 | +380.83% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $5.87 | +155.54% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $20.75 | +169.88% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $9.77 | +483.72% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $3.87 | +468.48% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.44 | +596.72% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.42 | +924.89% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $66.56 | -42.91% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $71.53 | -0.74% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $3.38 | +48.15% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $43.05 | -11.73% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $6.78 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.14 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $12.85 | +2,001.99% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $181.82 | - | 2 | Apr 23, 2020 |
Astria Therapeutics
Nov 12, 2025
Downgrades: Neutral
Price Target: n/a
Current: $13.10
Upside: -
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $7.86
Upside: +231.00%
Dianthus Therapeutics
Sep 9, 2025
Reiterates: Outperform
Price Target: $56 → $63
Current: $44.90
Upside: +40.33%
Korro Bio
Aug 13, 2025
Maintains: Strong Buy
Price Target: $153 → $147
Current: $6.97
Upside: +2,009.04%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $71.71
Upside: +14.35%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $7.56
Upside: +32.28%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $27.82
Upside: +0.67%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $1.11
Upside: +804.98%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $38.86
Upside: +167.63%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $3.56
Upside: +517.98%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.15
Upside: +552.68%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $122.42
Upside: -24.03%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $42.61
Upside: +59.59%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $22.05
Upside: +380.83%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $5.87
Upside: +155.54%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $20.75
Upside: +169.88%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $9.77
Upside: +483.72%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $3.87
Upside: +468.48%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.44
Upside: +596.72%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.42
Upside: +924.89%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $66.56
Upside: -42.91%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $71.53
Upside: -0.74%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $3.38
Upside: +48.15%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $43.05
Upside: -11.73%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $6.78
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.14
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $12.85
Upside: +2,001.99%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $181.82
Upside: -